Want to see LFCR full AI Analyst Report?
LFCR Stock Chart & Stats
$7.71
-$0.17(-2.79%)
At close: 4:00 PM EST
$7.71
-$0.17(-2.79%)
Day’s Range― - ―
52-Week Range$3.63 - $8.98
Previous CloseN/A
Volume140.23K
Average Volume (3M)208.02K
Market Cap
$175.54M
Enterprise Value$481.27
Total Cash (Recent Filing)$20.80M
Total Debt (Recent Filing)$150.14M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding37,509,407
10 Day Avg. Volume143,775
30 Day Avg. Volume208,018
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)-19.16
Price to Sales (P/S)2.10
P/FCF Ratio43.67
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside-15.69% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$122.18M
Bulls Say, Bears Say
Bulls Say
CDMO Business ModelLifecore’s core CDMO focus on sterile injectable development and fill-finish services aligns with durable outsourcing trends in pharma. Long lead times, regulatory barriers and customer stickiness create recurring fee-for-service revenue and structural demand for capacity and technical expertise.
Cash GenerationPositive operating cash flow and free cash flow provide near-term funding for operations, capex and debt service despite accounting losses. Sustainable cash generation reduces immediate refinancing pressure and creates optionality to invest in capacity or deleverage if maintained over multiple quarters.
Talent & Governance SupportApproval of a refreshed stock incentive plan and broad support for board and auditor signal governance continuity and a structural tool to retain/attract technical and commercial leadership. Strong retention capability supports execution of long-cycle manufacturing contracts and capacity planning.
Bears Say
High LeverageVery high debt relative to equity materially reduces financial flexibility and increases refinancing and interest-rate risk. Even with positive cash flow, leverage constrains investment, heightens default risk in downturns, and limits the company’s ability to pursue growth or absorb contract timing variability.
Persistent Net LossesSustained net losses weaken retained earnings and capital buffers, hindering reinvestment and making long-term margin improvement a prerequisite for durable viability. Losses also impede equity rebuild, amplify leverage metrics, and leave outcomes dependent on sustained operational improvement or structural revenue gains.
Declining RevenueAn 8% TTM revenue decline undermines operating leverage and raises questions about customer mix or capacity utilization. For a CDMO, lumpy contracts mean recoveries may be slow; persistent top-line weakness makes margin conversion uncertain and prolongs the path to consistent, durable profitability.
Lifecore Biomedical News
LFCR FAQ
What was Lifecore Biomedical, Inc.’s price range in the past 12 months?
Lifecore Biomedical, Inc. lowest stock price was $3.63 and its highest was $8.98 in the past 12 months.
What is Lifecore Biomedical, Inc.’s market cap?
Lifecore Biomedical, Inc.’s market cap is $175.54M.
When is Lifecore Biomedical, Inc.’s upcoming earnings report date?
Lifecore Biomedical, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Lifecore Biomedical, Inc.’s earnings last quarter?
Currently, no data Available
Is Lifecore Biomedical, Inc. overvalued?
According to Wall Street analysts Lifecore Biomedical, Inc.’s price is currently Overvalued.
Does Lifecore Biomedical, Inc. pay dividends?
Lifecore Biomedical, Inc. does not currently pay dividends.
What is Lifecore Biomedical, Inc.’s EPS estimate?
Lifecore Biomedical, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Lifecore Biomedical, Inc. have?
Lifecore Biomedical, Inc. has 37,509,407 shares outstanding.
What happened to Lifecore Biomedical, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lifecore Biomedical, Inc.?
Currently, no hedge funds are holding shares in LFCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Company Description
Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LFCR Stock 12 Month Forecast
Average Price Target
$6.50
▼(-15.69% Downside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
17.06% Insiders
6.34% Mutual Funds
46.64% Other Institutional Investors
22.72% Public Companies and
Individual Investors